GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.2600
8,484.786
d)
Aggregated information
Aggregated volume
Price
N/A (single transaction)
e)
Date of the transaction
2021-07-12
f)
Place of the transaction
London Stock Exchange (XLON)

Attachments

  • Original document
  • Permalink

Disclaimer

GSK - GlaxoSmithKline plc published this content on 14 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 July 2021 16:04:05 UTC.